B-cell lymphoma

Disease ID:1048
Name:B-cell lymphoma
Associated with:1 targets
0 immuno-relevant targets
2 immuno-relevant ligands
Database Links
Disease Ontology: DOID:707



Ligand Approved Immuno References Clinical comments
Clinical Use: Spebrutinib has been granted orphan drug designation by the EMA (using the chemical name n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide benzenesulfonic acid salt) for the treatment of B-cell chronic lymphocytic leukemia (CLL). Spebrutinib (as research code CC-292) has been compared with placebo as a co-therapy with for active rheumatoid arthritis, in completed clinical trial NCT01975610. In addition it is in various Phase I trials for B-cell lymphomas. Click here to view these trials at ClinicalTrials.gov.
Immuno Disease Comments: Phase 1 clinical candidate for B cell malignancies (see NCT01766583).
Clinical Use: GDC-0853 has reached Phase 2 clinical trial in patients with rheumatoid arthritis (RA: see NCT02833350), and Phase 1 in patients with resistant B-cell lymphoma or chronic lymphocytic leukemia (CLL).
Immuno Disease Comments: Phase 2 clinical candidate for B cell lymphoma (see NCT01991184).